Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers

Not Applicable

Completed

• Conditions: Diabetic Foot; Lower Extremity Wound
• Interventions: Other: Matrion; Other: Conventional Care Wound Management

• Registration Number: NCT05087758
• Lead Sponsor: LifeNet Health

Brief Summary

In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and the outermost chorionic layer, inclusive of the trophoblast layer. Matrion is minimally processed and disinfected using a proprietary decellularization technology and terminally sterilized that safely renders the placental membrane acellular and sterile for its intended surgical applications.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-10-10
• Study First Submitted QC: 2021-10-10
• Study First Posted: 2021-10-21
• Study Start: 2022-03-01
• Primary Completion: 2024-12-31
• Study Completion: 2025-02-28
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-28
• Last Update Posted: 2025-04-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

To be considered eligible to participate in the study, a subject must meet the inclusion criteria listed below:

1. Be male or female, between 21 and 80 years of age at the time of consent

2. For subjects with a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association, have been on a stable anti-diabetic treatment for at least 30 days before the baseline visit

3. Have a full-thickness wound of the lower extremity

4. Have a single target ulcer

5. Have a wound with an area greater than or equal to 1 cm2 and less than 25 cm2 and a depth less than or equal to 9 mm

6. Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:

   • Grade 1: superficial diabetic ulcer including the full skin thickness but not underlying tissue
   • Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess of osteomyelitis

7. Have an absence of infection based on Infectious Disease Society of America criteria

8. Have an adequate circulation to the affected lower extremity, defined as at least one these criteria:

   • Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mmHg
   • Ankle-brachial index (ABI) greater than 0.75
   • At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries

9. Have the ability to comply with off-loading (if required for specific wound) and dressing change requirements

10. Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments

11. Have provided written authorization for use and disclosure of protected health information

12. Have a life expectancy of greater than 6 months

Exclusion Criteria

To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:

1. Be pregnant or lactating
2. Have a wound that decreased in size ≥50% between the Screening and Baseline Visits
3. Have circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit
4. Have serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior to screening
5. Have a sensitivity to any of the following antibiotics: Lincomycin, Polymyxin B Sulfate, and/or Vancomycin
6. Have a sensitivity to N-Lauroyl Sarcosinate, and/or Benzonase® or Denarase®
7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the screening visit
8. Need for any additional concomitant dressing material other than the ones approved for this study
9. Have clinical signs of an infection at the study ulcer site
10. Have the inability to tolerate off-loading (a surgical shoe, removable cast walker or a total contact cast)
11. Have a known or suspected disease of the immune system
12. Have an active or untreated malignancy or active, uncontrolled connective tissue disease
13. Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the baseline visit
14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement
15. Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the baseline visit
16. Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening
17. Have evidence of active Charcot disease
18. Have undergone treatment with a living skin equivalent within the last 4 weeks before screening
19. Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
20. Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Matrion decellularized placental membrane	Matrion	Matrion placental membrane graft will be use to treat subjects diagnosed with a diabetic foot ulcer.
Conventional Care Wound Management	Conventional Care Wound Management	Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diabetic foot ulcer diagnosis.

Primary Outcome Measures

Name	Time	Method
Wound Healing	12 weeks	Proportion of chronic DFUs that have achieved complete wound closure

Secondary Outcome Measures

Name	Time	Method
Speed of Wound Closure	12 weeks	Time to wound closure measured from the baseline visit to the termination visit
Wound Area	12 weeks	Change in wound area over time
Grafts Used	12 weeks	Average number of Matrion grafts used per subject
Reoccurrence	6 months post termination visit	Rate of reoccurrence of wound post treatment
Infection	12 weeks	Rate of wound infection
Incidence of Treatment Emergent Adverse Events	12 weeks	Collection of adverse events, including changes in vital signs, ABI, and physical exams

Trial Locations

Locations (7)

Purvis-Moyer Foot and Ankle Center; 🇺🇸 Rocky Mount, North Carolina, United States

Compass Medical Research Center, LLC; 🇺🇸 Tucson, Arizona, United States

Center for Clinical Research, INC; 🇺🇸 San Francisco, California, United States

Limb Preservation Platform, INC; 🇺🇸 Fresno, California, United States

ILD Research Center; 🇺🇸 San Diego, California, United States

Doctors Research Network; 🇺🇸 Miami, Florida, United States

Albuquerque Associated Podiatrists; 🇺🇸 Albuquerque, New Mexico, United States